The immunotherapy pembrolizumab received FDA approval for first-line treatment of colon and rectal cancer

Metastatic or unresectable, microsatellite instability-high (MSI-H) or DNA mismatch repair-deficient (dMMR) forms of colorectal (large bowel) cancer can be treated in the first line with the immunotherapy pembrolizumab (Keytruda), which received approval on 29 June 2020 from the FDA. Pembrolizumab became the first immunotherapy approved as first-line treatment for this patient group, administered without giving patients chemotherapy.
Tumors with the genetic alterations called MSI-H and dMMR contain abnormalities that affect the proper repair of DNA within cells. The frequency of MSI-H varies by tumor type and stage, and approximately 5% of patients with metastatic colorectal cancer have MSI-H or dMMR tumors.
Pembrolizumab (Keytruda) works by blocking the cellular pathway of proteins known as PD-1 / PD-L1, which are found on the body’s immune cells and some cancer cells. By blocking this pathway, pembrolizumab can help the body’s immune system fight cancer cells and may benefit patients with MSI-H or dMMR metastatic colorectal cancer.
The study that led to FDA approval of immunotherapy for line 1 treatment of colorectal cancer
This FDA approval was based on the results of the multicenter, international, open-label, active-controlled, randomized KEYNOTE‑177 study comparing pemrolizumab with chemotherapy in 307 patients with metastatic colorectal cancer and MSI-H or dMMR tumors. This clinical trial showed a statistically significant improvement, as assessed by blinded independent review, in progression-free survival (PFS):
Median progression-free survival was 16.5 months in the pemrolizumab group and 8.2 months in the standard-of-care group. Longer-term analysis is required to assess the effect on survival.
Common side effects of pembrolizumab include fatigue, musculoskeletal pain, decreased appetite, itching/rash on the skin, diarrhea, nausea, rash, fever (pyrexia), cough, shortness of breath (dyspnea), constipation, pain and abdominal pain. Pembrolizumab can cause serious conditions known as immune-mediated adverse effects, such as inflammation of organs including the lungs (pneumonitis), colon (colitis), liver (hepatitis), endocrine glands (endocrinopathies) and kidneys (nephritis). Patients who experience severe or life-threatening infusion-related reactions should stop receiving pembrolizumab. Pregnant women should be informed that pembrolizumab may harm a developing fetus. Women who are breastfeeding should not use pembrolizumab because it may harm a breastfed child.
In conclusion, metastatic colorectal cancer is a serious, life-threatening disease with an unfavorable course. Chemotherapy combinations and other targeted cancer medicines currently offer longer survival compared with other cancer types, but prolonged treatments bring the problem of side effects. Having a non-chemotherapy option for a certain proportion of patients with metastatic colorectal cancer (MSI-H and dMMR-positive tumors) is a noteworthy advance in treatment. This approval also indicates that MSI-H and dMMR status should be investigated with genetic tests in patients newly diagnosed with advanced colorectal cancer.
*
Sources
fda.gov - 29 June 2020
Was this article helpful?
Your feedback helps us improve our content.





Reader comments
Share your comment
Your name and comment are published only after administrator approval. Your email address is never shown to visitors.
Be the first to comment.